Results 31 to 40 of about 26,503 (228)

Ketoconazole in the treatment of cryptococcosis of the central nervous system.

open access: yes, 1991
Two patients with cryptococcosis of the CNS were treated with ketoconazole (KTZ), an imidazole derivative with fungistatic properties; they had either failed standard therapy (Amphotericin-B + 5-Flurocytosine) or suffred intolerable side-effects to it ...
Sander, JW   +7 more
core   +1 more source

In vitro and in vivo ketoconazole sensitivity disparity in a cutaneous candidiasis case of Kluyveromyces marxianus: A case report [PDF]

open access: yes
Introduction: Cutaneous candidiasis is an infection caused by the yeast, Candida albicans or other Candida-related species. Recently, Candida infections of the skin have become more prevalent and could be attributed to an increase in the number of ...
Chioma Nnenna Nwofor
core   +1 more source

Ketoconazole administration reduces urinary cortisol levels.

open access: yes, 2012
Data are presented as mean ± SEM. *Significant difference for control vs.
Celeste C. Finnerty (165018)   +11 more
core   +1 more source

Melatonin ameliorates ketoconazole-induced increase in thyroid function

open access: yes, 2020
Background The antithyroid effect of ketoconazole has been reported. The secretion and action of melatonin in the thyroid gland are also known. However, the possible effect of melatonin on ketoconazole-induced antithyroid effect is unknown.
Alagbonsi, Abdullateef Isiaka   +6 more
core   +1 more source

Advanced nanotherapeutics for combating ocular infections: Rational design, antimicrobial mechanisms, and therapeutic breakthroughs

open access: yesBMEMat, EarlyView.
Nanomaterials revolutionize ocular infection treatment by enabling targeted drug delivery and enhanced antimicrobial efficacy against resistant pathogens. This review systematically explores their rational design, multimodal mechanisms, and translational potential for next‐generation anti‐infective therapies.
Yujia Liu   +7 more
wiley   +1 more source

Ketoconazole Binds to the Human Androgen Receptor

open access: yes, 1992
Ketoconazole, an imidazole anti-fungal agent, has often produced features of androgen deficiency including decreased libido, gynecomastia, impotence, oligospermia, and decreased testosterone levels, in men being treated for chronic mycotic infections ...
Eil, C.
core   +1 more source

Formulation and Evaluation of Ketoconazole Nano-suspension

open access: yes, 2023
The use of antifungals that are widely used by the public is ketoconazole. Ketoconazole is included in the Biopharmaceutical Classification System (BCS) II category, where the drug is poorly soluble in water but has high permeability.
Gita Deslia Sari, Eriska Agustin
core   +1 more source

Modelling of Behavior for Inhibition Corrosion of Bronze Using Artificial Neural Network (ANN)

open access: yesEntropy, 2018
In this work, three models based on Artificial Neural Network (ANN) were developed to describe the behavior for the inhibition corrosion of bronze in 3.5% NaCl + 0.1 M Na2SO4, using the experimental data of Electrochemical Impedance Spectroscopy (EIS ...
D. Elusaí Millán-Ocampo   +5 more
doaj   +1 more source

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 metabolizes various selective serotonin reuptake inhibitors (SSRIs) and genetic CYP2C19 variants are associated with SSRI tolerability and response. Yet, whether CYP2C19 variability also impacts citalopram response remained unclear. We here evaluated associations between CYP2C19 genotypes and citalopram prescription data of 11,079 patients from
Yoomi Park   +2 more
wiley   +1 more source

Systemic absorption of ketoconazole from vaginal pessaries.

open access: yes, 1984
Eight healthy female subjects were each given (a) ketoconazole 400 mg orally, (b) ketoconazole 400 mg as a single vaginal pessary, (c) ketoconazole 800 mg as two vaginal pessaries, and (d) ketoconazole 1200 mg as three vaginal pessaries.
MD Ene   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy